Archive · 21 Nov 2025
India's Aging Population to Drive Pharma Market Growth
India is getting older, and this will change how we think about healthcare and other services.
In the next 20-30 years, one-fourth of the pharma market will be for medicines that help older people with health issues like heart problems and arthritis.
This is because more people will be over 60, and they will need more medical care.
This change will also create new opportunities in areas like technology and housing that help older people live better lives.
India's 60-plus population will reach 20-30% by 2050, surging demand for elderly-care treatments
This demographic shift will make the 'silver generation' account for at least 25% of the pharma market in the next two-three decades
Cardiac, metabolic, neurological, and musculoskeletal medicines will dominate the market
Dependency ratios will flip, with elderly dependents becoming the dominant driver by 2100
The 'silver economy' will expand across healthcare, technology, housing, and financial services
- Who
- India's 60-plus population
- What
- will drive the growth of the pharma market
- When
- in the next two to three decades
- Where
- in India
- Why
- due to the country's demographic transition towards an elderly-heavy profile
Optimistic View
Pessimistic View
Economic Impact
Optimistic View
The demographic shift opens new opportunities in the 'silver economy'
Pessimistic View
The increased dependency on elderly care places a significant economic burden on households and the state
- Current 60-plus population
- about 11%
- Projected 60-plus population in 2050
- 20-21%
- Projected 60-plus population in 2100
- 31%
- Estimated silver generation's contribution to pharma market
- at least 25%
- Dominant medicines in the next several decades
- cardiac, metabolic, neurological, and musculoskeletal medicines